Global Hemoglobinopathy Market: Restraint
Failing clinical trials for the treatment of sickle cell anemia
The global hemoglobinopathy market can be hindered by failing of clinical trials for the treatment of sickle cell anemia. For instance, in April 2022, Imara Inc., a clinical-stage biopharmaceutical company, announced that an Imara drug that hits a novel target to treat rare, inherited hemoglobin disorders has failed two mid-stage studies, one for sickle cell disease and the other for beta thalassemia.
Hemoglobinopathy Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients